Calls
1
Dajun Yang
Co-Founder, Chairman and CEO, Ascentage Pharma
Win Rate
0.0%
return
-45.2%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 14
$27.48
-45.2%
Ascentage has achieved its 2025 milestones, completed a successful Nasdaq IPO, doubled or tripled its stock price, has sufficient cash through 2027, and its Takeda partnership plus global Phase 3 trial for lead drug validate its R&D and support commercialization in about two years.
Other
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Dajun Yang has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: CHINA BIOTECH, AAPG.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
